Advertisement
JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Burcelin, R.
Right arrow Articles by Charron, M. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Burcelin, R.
Right arrow Articles by Charron, M. J.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

J Biol Chem, Vol. 273, Issue 14, 8088-8093, April 3, 1998

In Vivo and in Vitro Regulation of Hepatic Glucagon Receptor mRNA Concentration by Glucose Metabolism*

Rémy BurcelinDagger §, Caroline Mrejen§par , Jean Francois Decauxpar , Sylvie Hauguel De Mouzonpar , Jean Girardpar , and Maureen J. CharronDagger **

From the Dagger  Department of Biochemistry, Albert Einstein College of Medicine, Bronx, New York 10461 and par  Centre de Recherche sur l'Endocrinologie Moléculaire et le Développement, CNRS, 92190 Meudon-Bellevue, France

    ABSTRACT
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

We have recently cloned the murine glucagon receptor (GR) gene and shown that it is expressed mainly in liver. In this organ, the glucagon-GR system is involved in the control of glucose metabolism as it initiates a cascade of events leading to release of glucose into the blood stream, which is a main feature in several physiological and pathological conditions. To better define the metabolic regulators of GR expression in liver we analyzed GR mRNA concentration in physiological conditions associating various glucose metabolic pathways in vivo and in vitro in the rat and in the mouse. First, we report that the concentration of the GR mRNA progressively increased from the first day of life to the adult stage. This effect was abolished when newborn rodents were fasted. Second, under conditions where intrahepatic glucose metabolism was active such as during fasting, diabetes, and hyperglycemic clamp, the concentration of GR mRNA increased independent of the origin of the pathway that generated the glucose flux. These effects were blunted when hyperglycemia was corrected by phlorizin treatment of diabetic rats or not sustained during euglycemic clamp.

In accordance with these observations, we demonstrated that the glycolytic substrates glucose, mannose, and fructose, as well as the gluconeognic substrates glycerol and dihydroxyacetone, increased the concentration of GR mRNA in primary cultures of hepatocytes from fed rats. Glucagon blunted the effect of glucose without being dominant. The stimulatory effect of those substrates was not mimicked by the nonmetabolizable carbohydrate L-glucose or the glucokinase inhibitor glucosamine or when hepatocytes were isolated from starved rats. In addition, inhibitors of gluconeogenesis and lipolysis could decrease the concentration of GR mRNA from hepatocytes of starved rats. Combined, these data strongly suggest that glucose flux in the glycolytic and gluconeogenic pathways at the level of triose intermediates could control expression of GR mRNA and participate in controlling its own metabolism.

    INTRODUCTION
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

The glucagon receptor (GR)1 is a 63,000-Da plasma membrane protein that belongs to a subfamily of peptide hormone receptors (1, 2). All members of this family contain seven transmembrane domains and are coupled with GTP-binding proteins. Upon binding to its receptor, glucagon initiates its action by activating several GTP-binding proteins which are rate-limiting steps in various signal transduction cascades (3-12).

The GR gene is expressed mainly in liver (2, 8, 13, 14) where it initiates a cascade of events leading to synthesis and release of glucose into the blood stream (15). Hepatic glucose production represents a major process in several physiological and pathological conditions. In newborns, glucagon is secreted within an hour of parturition and initiates several processes leading to hepatic glucose production (16) from glycogenolysis and gluconeogenesis (17). Then, during suckling glucagon stimulation ensures hepatic synthesis of glucose, which is otherwise poorly provided by mother's milk (18). Similarly, during starvation in adults glucose produced by the liver is the main energy source utilized by splanchnic tissues and brain (19). In pathological situations such as diabetes, elevated hepatic glucose production is one of the key features responsible for hyperglycemia (20). The GR is also expressed in pancreatic beta cells where its stimulation potentiates insulin secretion (21). Therefore, the GR plays a major role in regulation of glucose homeostasis. To more accurately understand its role(s) in regulation of glucose metabolism, we measured modulation of GR mRNA concentration in liver. We analyzed variations in hepatic GR mRNA concentration in mouse under physiological conditions and in rat under experimental conditions and primary cultures of hepatocytes to further define the in vivo conclusions.

    MATERIALS AND METHODS
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

In Vivo Studies in Mice

Mice (CBA) bred in our laboratory were housed at 24 °C with light from 0700 to 1900 h and free access to water and chow (72% carbohydrate, 1% fat, 27% protein; in percent of energy). To follow GR mRNA concentration during development 16-, 17-, 18-, and 19-day-old fetuses and 1-, 10-, 15-, 20-, and 28-day-old mice were sacrificed by cervical dislocation, and the livers were removed and frozen (n = 2-6/group). To study the influence of nutritional variations on GR mRNA concentration in liver, mice (n = 18) were weaned either with a high fat diet (n = 6) (18% carbohydrate, 58% fat, 24% protein; in percent of energy) or a high carbohydrate diet (n = 6) (63% carbohydrate, 11% fat, 26% protein; in percent of energy) (22), or a regular chow pellets (n = 6) for 2 weeks. At completion of the assay periods, mice were sacrificed by cervical dislocation, and livers were removed and frozen. In addition, mice (n = 6) were sacrificed during the dark period of their daily light cycle to ensure a fed state, and they are referred to as controls. Mice were sacrificed following a 2-day fast (n = 6) or fasted for 2 days and refed for 1 day (n = 5) and sacrificed in the postprandial state.

In Vivo Studies in Rats

One-day-old Wistar rats were fasted for 16 h (n = 9), and livers from these and 1-day suckling rats were removed and frozen.

Diabetes Induction-- Diabetes was induced by an intraperitoneal injection of 65 mg/kg of body weight of streptozotocin (STZ, Sigma) dissolved in 0.1 M ice-cold sodium citrate (23, 24). To avoid the lethaliy of hyperglycemia and hypoinsulinemia characteristic of long term insulin-dependent diabetes, female Wistar rats were mated at 9 weeks of age prior to injection of STZ. Indeed, development of insulin resistance during pregnancy may protect the mother from the deleterious effect of a lack of insulin (25, 26). In addition, elevated ketones are redistributed to the fetus to be used as fuel, which may be less deleterious to the mother (27, 28). The mating day was considered as day 1 of gestation and STZ injection. On day 3 post-STZ injection, blood was sampled from the tail vein, and diabetes was diagnosed when plasma glucose levels were higher than 16 mM. Diabetic rats (n = 9) were randomly chosen to receive a continuous subcutaneous infusion of phlorizin, an inhibitor of renal tubular glucose reabsorption (STZ, Sigma). Phlorizin, dissolved in a 40% (w/v) propylene glycol solution, was delivered at a rate of 0.4 mg/kg/day, via implantable osmotic pumps (Alzet, Charles River St. Aubin les Ebeuf, France), from the 14th day to the 19th day post-STZ, then livers were removed, frozen in liquid nitrogen, and stored at -80 °C.

Insulin and Glucose Infusions-- Indwelling catheters were inserted into the left jugular vein and right carotid artery under light ether anesthesia so six 1-day pregnant female Wistar rats could recover rapidly from surgery and be studied conscious. Clamps were performed on day 19 of pregnancy for 12 h as described previously (29). Blood samples were withdrawn from the carotid artery and glucose concentration checked with a glucose reflectance meter (One Touch II, Lifescan, Inc., Johnson & Johnson, Milpitas, USA). Upon completion, rats were sacrificed by cervical dislocation, livers immediately removed, frozen in liquid nitrogen and stored at -80 °C. All rats were sacrificed in the postprandial state and referred to as controls.

Primary Culture of Rat Hepatocytes

Isolation-- Hepatocytes were isolated from Wistar rats weighing 200 g at 0900 h, i.e. postabsorptive period or after a 24-h food removal, as described previously (29). Cell viability, estimated by trypan blue exclusion, was greater than 90%.

Primary Culture-- Hepatocytes were isolated from fed rats and suspended in Medium 199 containing Earle's salt, 2.2 mg/liter NaHCO3 (Life Technologies, Inc., Cergy-Pontoise, France) with penicillin (10 units/ml), streptomycin (100 µg/ml), kanamycin (50 µg/ml), and supplemented with 2% Ultroser (Life Technologies, Inc., Cergy-Pontoise, France). Hepatocytes were plated 8 × 106 cells/100-mm2 dish. After cell attachment (4 h), the medium was replaced by fresh Medium 199 containing hormones and nutrients as described in the figure legends. The inhibitors of gluconeogenesis mercaptopicolinate (MPA, dissolved in 150 mM HEPES and used at 1 mM) and lipolysis tetradecylglycidate (dissolved in 100% dimethyl sulfoxide and used at 40 µM) were added as indicated.

Quantification of Glucagon Receptor and GLUT2 mRNA

Total RNAs were isolated using a guanidine thiocyanate method and stored at -80 °C until use (30). Total RNAs (20 µg) were denatured, size-fractionated by electrophoresis, and transferred to nylon. The GLUT2 cDNA probe (31) was a gift from Dr. B. Thorens. Probes were labeled with [32P]dCTP using the Multiprime labeling system (Amersham, Bucks, UK). Hybridizations were performed in solutions containing 42% deionized formamide, 7.5% dextran sulfate, 8× Denhardt's solution, 40 mM Tris-HCl, pH 7.5, and 1% SDS at 42 °C overnight. Membranes were washed twice (30 min) with 2× SSC, 0.1% SDS, at 42 °C and twice (30 min) with 0.1× SSC, 0.1% SDS at 55 °C and exposed for 4-72 h at -80 °C with intensifying screens. Membranes were exposed to and quantitated by a PhosphorImager or by densitometric analysis.

To verify the integrity and equal loading of RNA, Northern blots were stained with methylene blue or hybridized with an oligonucleotide probe representing the sequence 1047-1070 of rat 18 S ribosomal RNA (32) labeled with [32P]ATP.

Statistical Analysis

Results are expressed as means ± S.E. Statistical analysis were performed by Student's t test for unpaired data. Statistical significance was reached for p < 0.05.

    RESULTS
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

GR mRNA Concentration in Mouse Liver during Development-- Traces of GR mRNA could be detected as early as 16 days of fetal life (Fig. 1A). The concentration of a 1.9-kilobase pair GR mRNA increased from the first day of postnatal life to adulthood (Fig. 1B). Some variability in the concentration of GR mRNA is observed at birth. When the mice were either weaned onto a high fat or high carbohydrate diet the concentration of GR mRNA was 210 and 250%, respectively, of mice weaned onto normal lab chow (Fig. 1C). In addition, a 450% increase in GR mRNA was observed following a 2-day fast compared with fed controls and 1 day of refeeding partly reversed this overexpression (Fig. 1D).


View larger version (33K):
[in this window]
[in a new window]
  		Fig. 1.   Developmental and nutritional regulation of the liver GR mRNA concentration in vivo. Northern blot analysis (left panels) of the in mouse liver. Quantification of liver GR mRNA in arbitrary units of the described mice is shown on the right panels. A and B, RNA from 16-19-day-old fetuses (f16-f19) and suckling 1-, 10-, 15-, 20-day-old and fed adult mouse liver were analyzed. 16-day-old fetuses were set as 100%. Four to six mice per group were studied. C, RNA from livers from 20-day-old mice and mice weaned onto a normal (NC), high fat (HFC), or high carbohydrate (HCC) diet were analyzed. Six mice per group were studied. NC were set as 100%. D, RNA from livers from mice fed (Control), 2 days fasted (2 D.Fast), and 1-day refed after a 2-day fast (1 D.Refed) were analyzed. Five to six mice per group were studied. Controls were set as 100%. The asterisk (*) indicates statistical significance for p < 0.05 between control and experimental group.

GR mRNA Concentration in Rat Liver in Different Experimental Conditions-- Results from the above studies on mouse liver demonstrated that expression of the GR in liver was mainly initiated at the newborn stage and was under the control of various nutritional stimuli. To accurately dissect apart the respective role of these factors, in vivo experiments were performed on rat liver.

First, 1-day-old newborn rats were fasted for 16 h. This treatment induced a dramatic decrease in GR mRNA concentration when compared with suckling rats (Fig. 2A). To analyze the effect of glycemic variations on liver GR mRNA concentration, STZ was injected to female rats to achieve hyperglycemia and induce hypoinsulinemia. Nineteen days after STZ injection plasma glucose level rose from 5.0 ± 0.1 mM to 27.0 ± 1.2 mM and insulin level dropped from 224 ± 18 pM to 42 ± 66 pM. Diabetes increased the concentration of GR mRNA by 250% in rat liver (Fig. 2B). When hyperglycemia was reduced from 27 to 12 mM by phlorizin treatment GR mRNA concentration decreased to reach a level similar to the control nondiabetic rats (Fig. 2B).


View larger version (36K):
[in this window]
[in a new window]
  		Fig. 2.   Regulation of the hepatic GR mRNA concentration in experimental conditions. Northern blot analysis of the GR mRNA concentration in vivo in rat liver (left panels). Quantification of liver GR mRNA in arbitrary units of the described rats is shown in the right panels. A, 1-day-old newborn rats were fasted for 16 h (NB1 Fasted) and compared with 1-day-old newborn rats suckling the mother's milk (NB1 Suckling). Eight rats per group were studied. NB1 Suckling was set as 100%. B, hyperglycemic hypoinsulinemic diabetic rats (STZ) and normoglycemic hypoinsulinemic phlorizin treated diabetic rats (STZ-Phlo) were compared with rats in postprandial state (Control). 18 S rRNA is shown to correct for loading differences between lanes. Six rats per group were studied. Controls were set as 100%. C, 12-h hyperinsulinemic hyperglycemic (HG) and 12-h hyperinsulinemic normoglycemic (HI) clamped rats were compared with rats in the postprandial state (Control). 18 S rRNA is shown to correct for loading differences between lanes. Six rats per group were studied. Controls were set as 100%. The asterisk (*) indicates statistical significance for p < 0.05 between control and experimental groups.

The effect of hyperinsulinemia (4.5 nM) in the presence or absence of hyperglycemia (26 mM) was tested at the end of 12 h of hyperinsulinemic euglycemic or hyperinsulinemic hyperglycemic clamp conditions. Hyperglycemia was necessary to maintain elevated GR mRNA concentration in rat liver after 12 h of hyperinsulinemia (Fig. 2C).

In Vitro Analyses-- To further dissect apart the effect of carbohydrate metabolism on the concentration of GR mRNA, primary cultures of rat hepatocytes were prepared. In hepatocytes cultured for 24 h the concentration of GR mRNA rose proportionally to increasing concentrations of glucose in the medium (Fig. 3A). Similar results were obtained when hepatocytes were cultured in the presence or absence of 10% fetal bovine serum (data not shown). Fructose and mannose induced the same stimulatory effect on GR mRNA concentration when present at 5 mM but not 25 mM (Fig. 3A). Conversely, the concentration of GLUT2 mRNA further increased under these conditions, suggesting that these two genes are differentially regulated (Fig. 3B). Incubation of hepatocytes with glucosamine, which inhibits glucokinase activity, was associated with a decrease in GR and GLUT2 mRNA concentrations. But, increasing the intracellular concentration of carbohydrate 6-phosphate by adding 2-deoxyglucose to the medium did not further increase the concentration of GR or GLUT2 mRNA (Fig. 3B). Similarly, L-glucose which is not metabolized did not influence the concentrations of GR or GLUT2 mRNA (Fig. 3B).


View larger version (54K):
[in this window]
[in a new window]
  		Fig. 3.   In vitro effects of various carbohydrates on GR and GLUT2 mRNA concentrations in primary rat hepatocytes. A, hepatocytes from fed rats were cultured 24 h in the presence of 0, 5, and 25 mM D-glucose or 5 and 25 mM D-mannose, D-fructose, D-glucosamine. 18 S rRNA is shown to correct for loading differences between lanes. Results are from four experiments. B, hepatocytes from fed rats were cultured 24 h in the presence of 0, 5, 25, and 40 mM D-glucose (D-Glc) or 25 and 40 mM L-glucose (L-Glc) or 25 mM 2-deoxyglucose (2DG). Results are from three experiments.

The presence of 25 mM glucose progressively increased the concentration of GR mRNA within 24 h (Fig. 4). Such an increase was not observed when hepatocytes were cultured in the absence of glucose (Fig. 4). The effect of insulin was assessed after 24 h of culture in the presence of several glucose concentrations and no changes were observed (Fig. 5).


View larger version (13K):
[in this window]
[in a new window]
  		Fig. 4.   Variations in GR mRNA in hepatocytes in vitro. Hepatocytes from fed rats were cultured for 0, 5, 14, and 24 h in the presence or absence of 25 mM glucose (G). Results are from three experiments.


View larger version (39K):
[in this window]
[in a new window]
  		Fig. 5.   Dose response of GR and GLUT2 mRNAs to glucose in the presence of insulin in rat hepatocytes. Hepatocytes from fed rats were cultured for 24 h in the presence or absence of 10-7 insulin and increasing concentrations of glucose. 18 S rRNA is shown to correct for loading differences between lanes.

When hepatocytes were isolated from fed rats and cultured in the absence of glucose but in the presence of the gluconeogenic substrates alanine dihydroxyacetone or glycerol, the concentration of GR mRNA increased (Fig. 6A). Interestingly, this effect was not observed in hepatocytes isolated from starved rats suggesting that the basal concentration of the GR mRNA, being already elevated due to the fasting state, could not be further increased under such conditions. Conversely, the concentration of GR mRNA was decreased when a gluconeogenic inhibitor MPA was added to the hepatocytes isolated from starved rats (Fig. 6B). The same results were obtained in the presence of tetradecylglycidate, an inhibitor of carnitine palmitoyltransferase-1, which reduces the oxidation of long chain acyl-CoA (Fig. 6B). In addition, when glucagon was added to hepatocytes isolated from fed rats it blunted the stimulatory effect of glucose without being dominant (Fig. 6C).


View larger version (17K):
[in this window]
[in a new window]
  		Fig. 6.   Effect of gluconeogenic substrates, glucagon, and inhibitors of gluconeogenesis and carnitine palmitoyltransferase-1 activity. A, hepatocytes isolated from fed or starved rats were cultured for 24 h in absence (G0, glucose- and substrate-free medium) or the presence of the gluconeogenic substrates glycerol (Gly, 10 mM), dihydroxyacetone (DHA, 10 mM), or alanine (Ala, 10 mM). B, hepatocytes isolated from starved rats were cultured for 24 h in a glucose-free medium supplemented with a mixture of lactate-pyruvate (10/1 mM) in the presence or absence of inhibitors tetradecylglycidate (TDGA) and MPA. C, hepatocytes isolated from fed rats were cultured for 24 h in the presence or absence of 0, 5, or 25 mM D-glucose and in the presence or absence of 100 nM glucagon. Quantifications from 3 Northern blots are diagrammed. The asterisk (*) indicates statistical significance for p < 0.05 between the control (G0 for A and C or lactate-pyruvate in B) and experimental conditions.

The stimulatory effect of glucose was further analyzed in the presence of cycloheximide to inhibit the translation process. In the presence of 20 mM glucose, when cycloheximide was added to the medium the concentration of GR mRNA further increased and a secondary signal of approximately 2.2 kilobase pairs was detected suggestive of alternative splicing of nontranslated exons (Fig. 7).


View larger version (40K):
[in this window]
[in a new window]
  		Fig. 7.   Effect of cycloheximide (Chx) on GR mRNA in hepatocytes in vitro. Hepatocytes from fed rats were cultured for 24 h in the presence of 25 mM of glucose and in the presence or the absence of 10 µM cycloheximide. Data shown is representative of three independent experiments.

    DISCUSSION
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

We report an analysis of the regulation of GR mRNA concentration in vivo in liver and in vitro in primary cultures of hepatocytes under various metabolic conditions which more accurately define the regulation of the glucagon-GR system.

GR mRNA was detected in liver from the first day of postnatal life and its concentration reached a maximum at the adult stage (Fig. 1). The perinatal period is associated with dramatic changes in hormonal and metabolic factors (16, 17). In the newborn, after a brief period of starvation, a drop in circulating glucose and insulin levels and an abrupt secretion of glucagon occur (16). Then the newborn pup feeds on a high fat, low carbohydrate diet of mother's milk. These hormones stimulate the synthesis and release of glucose by liver, initially from the breakdown of glycogen stores and then from neosynthesis of glucose using glycerol and amino acids as a carbon source provided by mother's milk (17). In addition, to meet energy needs of the newborn, the capacity for fatty acid oxidation develops rapidly after birth by many tissues including liver where it results in a high rate of ketone body production (17). Liver GR mRNA increased markedly in 16 h milk fed newborns, whereas the increase was prevented when pups were fasted from birth (Fig. 3A). Interestingly, after a 16-h fasting period the concentration of GR mRNA dramatically decreased (Fig. 3A). In this condition glycogen stores were depleted and plasma free fatty acids and the rate of lipid oxidation were very low (17). The carbon substrates, in the form of low circulating concentrations of glycerol and amino acids necessary to fuel the gluconeogenesis pathway, were no longer supplied by mother's milk (17). As a main consequence blood glucose levels remained low. This important finding suggests that impairment of the increase in GR mRNA concentration could be due to low circulating blood glucose and free fatty acid concentrations. Stimulation of glucose and free fatty acid metabolism in liver could trigger and progressively increase the concentration of GR mRNA. This switch is important as it could mediate the characteristic gluconeogenic effect of glucagon during the suckling period by initiating GR mRNA expression at birth. Conversely, in adult mice, the fasting state induced an opposite effect by increasing GR mRNA concentration in liver (Fig. 1D). Under these conditions lactate and gluconeogenic amino acid substrates are adequately available. As a consequence, gluconeogenesis is very active and GR mRNA concentration is elevated compared with mice studied in the post-prandial state despite low blood glucose concentrations (33). This suggests that flux of glucose and its metabolism in liver, rather than the glucose level per se, could regulate expression of the GR gene. Similarly, increasing liver gluconeogenesis and lipid metabolism using a high fat, low carbohydrate diet further increased the concentration of GR mRNA (Fig. 1C). The same observation was made in STZ-treated diabetic rats (Fig. 2B), a situation where gluconeogenesis and lipolysis are indeed dramatically stimulated (34). Interestingly, partial correction of hyperglycemia with the glucosuric agent phlorizin restored to normal the concentration of GR mRNA (Fig. 2B). In the condition of long term phlorizin infusion, the concentration of circulating glucagon decreased and GLUT2, glucokinase, glucose 6-phosphatase, and phosphoenolpyruvate carboxykinase mRNA levels were partially or fully normalized as a consequence of gluconeogenesis (35-37). Similarly liver function, as measured by glucose production, was corrected (38). These in vivo results suggest that an intermediary metabolite or a factor involved in the gluconeogenic/glycolytic pathways could mediate the increase in GR mRNA concentration in liver. It has recently been demonstrated that elevated plasma free fatty acid levels could stimulate expression of genes such as carnitine palmitoyltransferase 1 (39).

To determine if this increase was indeed linked to the gluconeogenic pathway, rats were studied under conditions where gluconeogenesis was totally inhibited such as during insulin infusion (40-42). After 12 h of hyperinsulinemia hepatic glucose production was totally inhibited and the concentration of GR mRNA remained normal or slightly lower than in control post-prandial rats. Simultaneous infusion of glucose to induce hyperglycemia and stimulation of glucose metabolism in liver was necessary to maintain a high concentration of GR mRNA (Fig. 2C). Most of the data reported here show that GR mRNAs increase in vivo under gluconeogenic conditions (i.e. suckling newborns, fasting, diabetes).

The above results further emphasize that glucose, beside its role as a nutrient, could regulate, through some intermediates of its metabolism, GR gene expression (43, 44). This observation is reinforced by our in vitro results and data from others (45), which showed that glucose increased GR mRNA concentration in primary cultures of hepatocytes (Fig. 3). Glucose in liver is mainly metabolized by the rate-limiting enzyme glucokinase (46). Interestingly, mannose and fructose, which do not need glucokinase to be metabolized, increased glucose 6-phosphate concentration (Fig. 8) (47, 48) and gave similar results with lower concentration of the carbohydrate (Fig. 3A). It is noteworthy that these carbohydrates at high concentration decreased GR mRNA concentration. This could be associated with a depletion of ATP content (49) and an inhibition of glucokinase activity (47, 50-52). This effect was not observed for GLUT2 expression, stressing the differential regulation of the two genes (Fig. 3A). The increase in GR mRNA concentration could not be mimicked by the nonmetabolizable sugar L-glucose or by glucosamine which inhibits glucokinase (Figs. 3, A and B). The effect of glucose was not observed when hepatocytes were isolated from 48-h fasted rats, i.e. when glucokinase activity was very low (data not shown). The stimulatory effect of glucose could also be observed over time as the concentration of GR mRNA increased when hepatocytes were cultured for 24 h in the presence of a high glucose concentration (Fig. 4). No effect was observed in the absence of glucose or when insulin was combined with glucose (Fig. 5). These results could suggest that glucokinase activity and the accumulation of its product glucose 6-phosphate contributed to the increase in concentration of GR mRNA. However, addition of 2-deoxyglucose to the medium that mainly accumulated as 2-deoxyglucose 6-phosphate did not increase the concentration of GR mRNA in primary cultures of hepatocytes. A metabolite further down the glycolytic pathway from glucose 6-phosphate and common to the gluconeogenic pathway could be responsible (Fig. 8). Indeed, when gluconeogenic substrates dihydroxyacetone or glycerol were added to primary cultures of hepatocytes isolated from fed rats the concentration of GR mRNA increased (Fig. 6A). In hepatocytes isolated from fed rats, dihydroxyacetone and glycerol are minimally converted into glucose but mainly converted into lactate and pyruvate (Fig. 8) (53). The same results were obtained with alanine, which further reinforces the hypothesis that a metabolite distal to glucose 6-phosphate and the flux of carbohydrate intermediates, possibly a triose, could regulate the concentration of GR mRNA. Indeed, when gluconeogenesis was inhibited at the level of PEPCK by MPA the concentration of GR mRNA was reduced (Fig. 6B) (54). Similarly, tetradecylglycidate, which inhibits carnitine palmitoyltransferase-1 activity and oxidation of long chain fatty acyl-CoA, reduced the concentration of GR mRNA (Fig. 6B). This is consistent with metabolic scenarios in which lipolysis is enhanced (i.e. diabetes, fasting, and birth). The ratios of NADH/NAD+ and ATP/ADP are increased in livers of diabetic and fasted animals due to increased lipolysis generating elevated amounts of citrate, acetyl-CoA and ketones (55-57). It has been shown that the redox state could control expression of genes involved in glucose metabolism (58) and therefore it is possible that nicotinamide nucleotides and products of lipolysis could be involved in regulation of GR mRNA concentration. Our in vivo and in vitro results suggest that lipolysis, in addition to glucose metabolism, could be involved in regulation of GR mRNA. Current experiments are ongoing to further dissect apart the regulatory role of fatty acid metabolism.


View larger version (20K):
[in this window]
[in a new window]
  		Fig. 8.   Schematic representation of glucose metabolism pathways in liver during fed and fasted states. The solid and dotted lines represent the major and minor distribution of stubstrates into the metabolic pathways, respectively. DHA, dihydroxyacetone; OAA, oxaloacetate; PEP, phosphoenolpyruvate.

This effect of glucose on gene expression has been proposed for several hepatic genes such as L-pyruvate kinase, S14, fatty acid synthase, GLUT2 (29, 36, 59-61) and others where elevated concentrations of glucose 6-phosphate generated in the presence of insulin by a highly activated glucokinase seemed to be the mediator of the glucose metabolism effect. We report here that in the absence of glucokinase activity such as during STZ-diabetes or fasting state (36), augmentation of glucose flux through gluconeogenesis could also increase the concentration of GR mRNA in liver, an observation not reported for the precited genes.

In conclusion, analysis of the regulation of GR mRNA concentration in vivo and in vitro strongly suggest that variations in glucose flux in liver, rather than a specific metabolic pathway, controls expression of the GR gene. Our results provide references for future determination of the metabolites and secondary messengers common between the gluconeogenic and glycolytic pathways that are involved in these regulations.

    ACKNOWLEDGEMENTS

We thank Drs. L. Rossetti, E. B. Katz, T. S. Tsao, J. P. Pegorier, J. Li, and F. Rencurel for fruitful discussions through this study. We greatly thank and appreciate the technical expertise of Dr. Catherine Postic and J. Kande in performing the surgical procedure and infusions and B. Gouhot.

    FOOTNOTES

* This work was supported in part by National Institutes of Health Grant DK47425 and the American Diabetes Association grant (to M. J. C.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§ These authors contributed equally to this work.

Recipient of fellowships from the Juvenile Diabetes Foundation International and the Philippe Foundation.

** Scholar of the PEW Charitable Trust. To whom correspondence should be addressed: Dept. of Biochemistry, Albert Einstein College of Medicine, 1300 Morris Park Ave., Bronx, NY 10461. Tel.: 718-430-2852; Fax: 718-430-8676; E-mail: charron{at}aecom.yu.edu.

1 The abbreviations used are: GR, glucagon receptor; MPA, mercaptopicolinate; STZ, streptozotocin.

    REFERENCES
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

  1. Segre, G. V., and Goldring, S. R. (1993) Trends Endocrinol. Metab. 4, 309-314[CrossRef][Medline] [Order article via Infotrieve]
  2. Burcelin, R., Katz, E. B., and Charron, M. J. (1996) Diabetes Metab. 22, 373-396[Medline] [Order article via Infotrieve]
  3. Birnbaumer, L., Pohl, S. L., Rodbell, M., and Sundby, F. (1972) J. Biol. Chem. 247, 2038-2043[Abstract/Free Full Text]
  4. Lin, M. C., Salomon, Y., Rendell, M., and Rodbell, M. (1975) J. Biol. Chem. 250, 4246-4252[Abstract/Free Full Text]
  5. Rendell, M., Salomon, Y., Lin, M. C., Rodbell, M., and Berman, M. (1975) J. Biol. Chem. 250, 4253-4260[Abstract/Free Full Text]
  6. Salomon, Y., Lin, M. C., Londos, C., Rendell, M., and Rodbell, M. (1975) J. Biol. Chem. 250, 4239-4245[Abstract/Free Full Text]
  7. Rodbell, M. (1978) Natl. Cancer Inst. Monogr. 48, 271-276
  8. Lok, S., Kuijper, J. L., Jelinek, L. J., Kramer, J. M., Whitmore, T. E., Sprecher, C. A., Mathewes, S., Grant, F. J., Biggs, S. H., Rosenberg, G. B., et al.. (1994) Gene (Amst.) 140, 203-209[CrossRef][Medline] [Order article via Infotrieve]
  9. Wakelam, M. J., Murphy, G. J., Hruby, V. J., and Houslay, M. D. (1986) Nature 323, 68-71[CrossRef][Medline] [Order article via Infotrieve]
  10. Unson, C. G., Gurzenda, E. M., and Merrifield, R. B. (1989) Peptides 10, 1171-1177[CrossRef][Medline] [Order article via Infotrieve]
  11. Gehnrich, S. C., Gekakis, N., and Sul, H. S. (1988) J. Biol. Chem. 263, 11755-11759[Abstract/Free Full Text]
  12. Volz, A., Goke, R., Lankat-Buttgereit, B., Fehmann, H. C., Bode, H. P., and Goke, B. (1995) FEBS Lett. 373, 23-29[CrossRef][Medline] [Order article via Infotrieve]
  13. Burcelin, R., Li, J., and Charron, M. J. (1995) Gene (Amst.) 164, 305-310[CrossRef][Medline] [Order article via Infotrieve]
  14. Jelinek, L. J., Lok, S., Rosenberg, G. B., Smith, R. A., Grant, F. J., Biggs, S., Bensch, P. A., Kuijper, J. L., Sheppard, P. O., Sprecher, C. A., et al.. (1993) Science 259, 1614-1616[Abstract/Free Full Text]
  15. Unger, R. H. (1985) Diabetologia 28, 574-578[Medline] [Order article via Infotrieve]
  16. Girard, J. R., Cuendet, G. S., Marliss, E. B., Kervran, A., Rieutort, M., and Assan, R. (1973) J. Clin. Invest. 52, 3190-3200
  17. Girard, J., Ferre, P., Pegorier, J. P., and Duee, P. H. (1992) Physiol. Rev. 72, 507-562[Free Full Text]
  18. Girard, J. (1990) Biol. Neonate 1, 3-15
  19. Heath, D. F., Frayn, K. N., and Rose, J. G. (1977) Biochem. J. 162, 653-657[Medline] [Order article via Infotrieve]
  20. Unger, R. H., and Orci, L. (1982) Compr. Ther. 8, 53-59
  21. Kofod, H., Unson, C. G., and Merrifield, R. B. (1988) Int. J. Pept. Protein Res. 32, 436-440[Medline] [Order article via Infotrieve]
  22. Decaux, J. F., Ferre, P., and Girard, J. (1986) Biol. Neonate 50, 331-336[Medline] [Order article via Infotrieve]
  23. Burcelin, R., Printz, R. L., Kande, J., Assan, R., Granner, D. K., and Girard, J. (1993) Am. J. Physiol. 265, E392-E401[Abstract/Free Full Text]
  24. Boileau, P., Mrejen, C., Girard, J., and Hauguel-de Mouzon, S. (1995) J. Clin. Invest. 96, 309-317
  25. Ramos, P., and Herrera, E. (1995) Am. J. Physiol. 269, E858-E863[Abstract/Free Full Text]
  26. Boden, G. (1996) Obstet. Gynecol. Clin. North Am. 23, 1-10[CrossRef][Medline] [Order article via Infotrieve]
  27. Tanigawa, K., Ohguni, S., Masaki, Y., Tsuchiyama, S., Kawaguchi, M., and Kato, Y. (1989) Endocrinol. Jpn. 36, 195-201[Medline] [Order article via Infotrieve]
  28. Shambaugh, G. E. d. (1985) Fed. Proc. 44, 2347-2351[Medline] [Order article via Infotrieve]
  29. Postic, C., Burcelin, R., Rencurel, F., Pegorier, J. P., Loizeau, M., Girard, J., and Leturque, A. (1993) Biochem. J. 293, 119-124
  30. Chomczynski, P., and Sacchi, N. (1987) Anal. Biochem. 162, 156-159[Medline] [Order article via Infotrieve]
  31. Thorens, B., Sarkar, H. K., Kaback, H. R., and Lodish, H. F. (1988) Cell 55, 281-290[CrossRef][Medline] [Order article via Infotrieve]
  32. Chan, Y. L., Gutell, R., Noller, H. F., and Wool, I. G. (1984) J. Biol. Chem. 259, 224-230[Abstract/Free Full Text]
  33. Randle, P. J., Kerbey, A. L., and Espinal, J. (1988) Diabetes Metab. Rev. 4, 623-638[Medline] [Order article via Infotrieve]
  34. Rossetti, L., Giaccari, A., Barzilai, N., Howard, K., Sebel, G., and Hu, M. (1993) J. Clin. Invest. 92, 1126-1134
  35. Brichard, S. M., Henquin, J. C., and Girard, J. (1993) Diabetologia 36, 292-298[CrossRef][Medline] [Order article via Infotrieve]
  36. Burcelin, R., Eddouks, M., Kande, J., Assan, R., and Girard, J. (1992) Biochem. J. 288, 675-679
  37. Massillon, D., Barzilai, N., Chen, W., Hu, M., and Rossetti, L. (1996) J. Biol. Chem. 271, 9871-9874[Abstract/Free Full Text]
  38. Rossetti, L., Smith, D., Shulman, G. I., Papachristou, D., and DeFronzo, R. A. (1987) J. Clin. Invest. 79, 1510-1515
  39. Chatelain, F., Kohl, C., Esser, V., McGarry, J. D., Girard, J., and Pegorier, J. P. (1996) Eur. J. Biochem. 235, 789-798[Medline] [Order article via Infotrieve]
  40. Myers, S. R., Diamond, M. P., Adkins-Marshall, B. A., Williams, P. E., Stinsen, R., and Cherrington, A. D. (1991) Metabolism 40, 66-71[CrossRef][Medline] [Order article via Infotrieve]
  41. Cherrington, A. D., Pagliassotti, M. J., Myers, S. R., Adkins-Marshall, B., and McGuinness, O. P. (1991) J. Parenter. Enteral. Nutr. 15, 71S-73S[Abstract/Free Full Text]
  42. Adkins-Marshall, B. A., Myers, S. R., Hendrick, G. K., Williams, P. E., Triebwasser, K., Floyd, B., and Cherrington, A. D. (1990) Diabetes 39, 87-95[Abstract]
  43. Towle, H. C. (1995) J. Biol. Chem. 270, 23235-23238[Free Full Text]
  44. Girard, J., Ferre, P., and Foufelle, F. (1997) Annu. Rev. Nutr. 17, 325-352[CrossRef][Medline] [Order article via Infotrieve]
  45. Abrahamsen, N., Lundgren, K., and Nishimura, E. (1995) J. Biol. Chem. 270, 15853-15857[Abstract/Free Full Text]
  46. Pilkis, S. J., and Granner, D. K. (1992) Annu. Rev. Physiol. 54, 885-909[CrossRef][Medline] [Order article via Infotrieve]
  47. Van Schaftingen, E., and Davies, D. R. (1991) FASEB J. 5, 326-330[Abstract]
  48. Van Schaftingen, E., and Vandercammen, A. (1989) Eur. J. Biochem. 179, 173-177[Medline] [Order article via Infotrieve]
  49. Younus, M. J., Jouhal, K., and Butterworth, P. J. (1994) Biochim. Biophys. Acta 1190, 444-448[Medline] [Order article via Infotrieve]
  50. Vandercammen, A., and Van Schaftingen, E. (1990) Eur. J. Biochem. 191, 483-489[Medline] [Order article via Infotrieve]
  51. Davies, D. R., Detheux, M., and Van Schaftingen, E. (1990) Eur. J. Biochem. 192, 283-289[Medline] [Order article via Infotrieve]
  52. Vandercammen, A., and Van Schaftingen, E. (1991) Eur. J. Biochem. 200, 545-551[Medline] [Order article via Infotrieve]
  53. Pilkis, S. J., Riou, J. P., and Claus, T. H. (1976) J. Biol. Chem. 251, 7841-7852[Abstract/Free Full Text]
  54. Agius, L., Tosh, D., and Peak, M. (1993) Biochem. J. 289, 255-262
  55. Sochor, M., Ball, M. R., and Baquer, N. Z. (1988) Biochem. Int. 16, 15-23[Medline] [Order article via Infotrieve]
  56. Ferraz, M., Brunaldi, K, Oliveira, C. E., and Bazotte, R. B. (1997) Res. Commun. Mol. Pathol. Pharmacol. 95, 147-155[Medline] [Order article via Infotrieve]
  57. Lepine, A. J., Watford, M., Boyd, R. D., and Whitehead, D. M. (1993) Br. J. Nutr. 70, 81-91[CrossRef][Medline] [Order article via Infotrieve]
  58. Lane, R. H., and Flozak, A. S. (1996) Pediatr. Res. 39, 390-394[Medline] [Order article via Infotrieve]
  59. Decaux, J. F., Antoine, B., and Kahn, A. (1989) J. Biol. Chem. 264, 11584-11590[Abstract/Free Full Text]
  60. Shih, H. M., and Towle, H. C. (1992) J. Biol. Chem. 267, 13222-13228[Abstract/Free Full Text]
  61. Prip-buus, C., Perdereau, D., Foufelle, F., Maury, J., Ferre, P., and Girard, J. (1995) Eur. J. Biochem. 230, 309-315[Medline] [Order article via Infotrieve]

Copyright © 1998 by The American Society for Biochemistry and Molecular Biology, Inc.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Genome ResHome page
M. P. Keller, Y. Choi, P. Wang, D. Belt Davis, M. E. Rabaglia, A. T. Oler, D. S. Stapleton, C. Argmann, K. L. Schueler, S. Edwards, et al.
A gene expression network model of type 2 diabetes links cell cycle regulation in islets with diabetes susceptibility
Genome Res., May 1, 2008; 18(5): 706 - 716.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
S. Polakof, J. M. Miguez, and J. L. Soengas
In vitro evidences for glucosensing capacity and mechanisms in hypothalamus, hindbrain, and Brockmann bodies of rainbow trout
Am J Physiol Regulatory Integrative Comp Physiol, September 1, 2007; 293(3): R1410 - R1420.
[Abstract] [Full Text] [PDF]

Home page
 J. Physiol.Home page
A. Charbonneau, C. G. Unson, and J.-M. Lavoie
High-fat diet-induced hepatic steatosis reduces glucagon receptor content in rat hepatocytes: potential interaction with acute exercise
J. Physiol., February 15, 2007; 579(1): 255 - 267.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
A. Charbonneau, A. Melancon, C. Lavoie, and J.-M. Lavoie
Alterations in hepatic glucagon receptor density and in Gs{alpha} and Gi{alpha}2 protein content with diet-induced hepatic steatosis: effects of acute exercise
Am J Physiol Endocrinol Metab, July 1, 2005; 289(1): E8 - E14.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
H. Zhao, S. Yakar, O. Gavrilova, H. Sun, Y. Zhang, H. Kim, J. Setser, W. Jou, and D. LeRoith
Phloridzin Improves Hyperglycemia But Not Hepatic Insulin Resistance in a Transgenic Mouse Model of Type 2 Diabetes
Diabetes, November 1, 2004; 53(11): 2901 - 2909.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
N. Gorovits, L. Cui, J. V. Busik, M. Ranalletta, S. H. de-Mouzon, and M. J. Charron
Regulation of Hepatic GLUT8 Expression in Normal and Diabetic Models
Endocrinology, May 1, 2003; 144(5): 1703 - 1711.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
F. Smih, P. Rouet, S. Lucas, A. Mairal, C. Sengenes, M. Lafontan, S. Vaulont, M. Casado, and D. Langin
Transcriptional Regulation of Adipocyte Hormone-Sensitive Lipase by Glucose
Diabetes, February 1, 2002; 51(2): 293 - 300.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
A. Legare, R. Drouin, M. Milot, D. Massicotte, F. Peronnet, G. Massicotte, and C. Lavoie
Increased density of glucagon receptors in liver from endurance-trained rats
Am J Physiol Endocrinol Metab, January 1, 2001; 280(1): E193 - E196.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
R. Burcelin, M. del Carmen Munoz, M.-T. Guillam, and B. Thorens
Liver Hyperplasia and Paradoxical Regulation of Glycogen Metabolism and Glucose-sensitive Gene Expression in GLUT2-null Hepatocytes. FURTHER EVIDENCE FOR THE EXISTENCE OF A MEMBRANE-BASED GLUCOSE RELEASE PATHWAY
J. Biol. Chem., April 6, 2000; 275(15): 10930 - 10936.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
L. Portois, B. Maget, M. Tastenoy, J. Perret, and M. Svoboda
Identification of a Glucose Response Element in the Promoter of the Rat Glucagon Receptor Gene
J. Biol. Chem., March 19, 1999; 274(12): 8181 - 8190.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Burcelin, R.
Right arrow Articles by Charron, M. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Burcelin, R.
Right arrow Articles by Charron, M. J.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 1998 by the American Society for Biochemistry and Molecular Biology.
Advertisement
spacer
Advertisement
Advertisement